References UK clinical guidance from the NHS, the British HIV Association (BHIVA), and the British Association for Sexual Health and HIV (BASHH). Last updated: April 2026.
If you have both HIV and hepatitis B, your treatment plan needs to address both viruses simultaneously. The good news is that several drugs used for HIV also treat hepatitis B, so in most cases a single regimen covers both infections. The most important rule is never to stop hepatitis B-active drugs without medical supervision, because doing so can trigger a severe liver flare.
Here’s how hepatitis B is treated when you also have HIV.
Order a discreet home HIV test
Drugs That Treat Both HIV and Hepatitis B
| Drug | HIV Activity | Hepatitis B Activity |
|---|---|---|
| Tenofovir (TDF or TAF) | Yes | Strong |
| Emtricitabine | Yes | Moderate |
| Lamivudine | Yes | Moderate (but resistance develops easily) |
| Entecavir | Weak | Strong (used for hepatitis B alone) |
Recommended Approach
UK guidelines (BHIVA) recommend that HIV/hepatitis B co-infected patients should take an ART regimen containing tenofovir (TDF or TAF) as the backbone. This provides the strongest anti-hepatitis B activity and has a high barrier to hepatitis B resistance.
Suitable regimens include:
- Biktarvy (bictegravir + emtricitabine + TAF)
- Symtuza (darunavir + cobicistat + emtricitabine + TAF)
- Triumeq + tenofovir (less common)
Not suitable: Dovato (dolutegravir + lamivudine) — lamivudine alone has a high rate of hepatitis B resistance.
The Flare Risk
If you stop tenofovir, emtricitabine or lamivudine, hepatitis B can reactivate rapidly. This causes a sudden spike in liver inflammation (ALT flare) that can be severe or even fatal. This happens because the immune system was relying on the drugs to suppress hepatitis B, and removing that suppression allows massive viral replication.
Key rules:
- Never stop hepatitis B-active drugs without medical guidance
- If switching ART, ensure the new regimen still covers hepatitis B
- Your HIV team should always be aware of your hepatitis B status
Monitoring
- Hepatitis B viral load (HBV DNA) — checked regularly to confirm suppression
- Liver enzymes (ALT, AST) — checked at every routine visit
- Hepatitis B surface antigen (HBsAg) — checked periodically; loss indicates functional cure
- Liver fibrosis assessment — FibroScan or equivalent
- Liver cancer screening — ultrasound every 6 months if cirrhosis is present
Can Hepatitis B Be Cured?
Functional cure (HBsAg loss) happens in a small percentage of co-infected people on treatment. It’s more likely with effective HIV/HBV treatment over many years. Most people will need lifelong treatment to keep both viruses suppressed.
Read more: Hepatitis B and HIV overview | Biktarvy | What is HIV?
Frequently Asked Questions
Can I take Dovato if I have hepatitis B?
No. Dovato contains only lamivudine, which is not strong enough alone against hepatitis B and can cause resistance. You need a tenofovir-containing regimen.
What happens if I accidentally stop my medication?
Contact your HIV clinic urgently. They will monitor your liver function closely and restart treatment as soon as possible to prevent a serious flare.
Should I get the hepatitis B vaccine if I’m already co-infected?
No — vaccination is for prevention. If you already have chronic hepatitis B, the vaccine won’t help. Treatment is the priority.
Related reading
- Blood Test for Syphilis, Hepatitis B and Hepatitis C
- Can You Die From Hepatitis B?
- What Is Hepatitis A?
- What Is Hepatitis B?
- Hepatitis B Core Antibody Test Explained
Sources
- NHS — Sexual health conditions
- BASHH — UK clinical guidelines for STI management
- British HIV Association (BHIVA) — HIV treatment guidelines
- Terrence Higgins Trust — sexual health information
- UK Health Security Agency — STI surveillance data
Steve Page is a recognised expert on Sexually Transmitted Diseases (STDs) and STD treatments, having published numerous articles in peer-reviewed journals and presented his research at conferences around the world. He has an in-depth understanding of the latest medical research on STDs, and is an advocate for the development of new treatments and protocols to improve the health of those affected. In addition to his research, he has dedicated his career to understanding the causes and symptoms of STDs, as well as how to best treat those impacted.
